BCD-106 is an originator investigational product.
BCD-106 is an investigational product that is a bispecific monoclonal antibody to surface antigen CD471 and programmed death ligand 1 (PD-L1), potentially having immunostimulatory activity.
A monoclonal antibody is a protein created by scientists in the laboratory, which is equivalent to natural immune system antibodies and designed to bind to a specific target in the human body2.
BCD-106 is one of the medicinal products in BIOCAD’s clinical development program.
- CD47, cluster of differentiation 47.
- Weiner LM, Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.
This website section contains information about the clinical trial of an unauthorized investigational medicinal product for human use.